Pharma News, 2024

The FDA has approved Lumify Preservative Free eye drops for the treatment of ocular redness due to minor eye irritations, according to a press release from manufacturer Bausch + Lomb.

With the approval of X4 Pharmaceuticals’ first product mavorixafor, there’s a new commercial rare disease player in town.

The new method could help to prevent severe side effects caused by enantiomer drugs.

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

Pfizer will offer a warranty program for its first FDA-approved gene therapy.

The U.S. flu season appears to be over. It was long, but it wasn't unusually severe.

The government of Colombia has issued its first-ever compulsory license to enable access to generic versions of the key HIV medicine dolutegravir, without permission from the patent owner, ViiV Health...

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.

Whereas previous studies have shown aspirin use decreases incidence and mortality of colorectal cancer, researchers may now have insight into why this occurs, according to study results published in C...